ESMO Breast 2023 | Personalized ctDNA during neoadjuvant therapy in pts with early-stage breast cancer

Mridula George, MD, Rutgers Cancer Institute, New Brunswick, NJ, provides an overview of a study aimed to evaluate the feasibility of using ctDNA testing to monitor treatment response in patients with early breast cancer (eBC) undergoing neoadjuvant therapy (NAT). A personalized ctDNA assay was used to analyze plasma samples collected from 34 eBC patients at baseline and during treatment. The results showed that ctDNA detection was feasible, with ctDNA being detected in 85% of patients at baseline. The study also found that ctDNA monitoring during NAT could facilitate real-time assessment of treatment response and predict pathologic complete response. The study highlights the potential of ctDNA testing as a minimally invasive approach for monitoring treatment response in eBC patients. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.